![POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS](https://www.natap.org/2020/images/112020/112020-14/1120202.gif)
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS
![Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV) Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV)](https://www.natap.org/2018/images%20/121718/121918-4/1217185.gif)
Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV)
![Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB) (Global Hepatitis Summit 2023 April 28 Paris) Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB) (Global Hepatitis Summit 2023 April 28 Paris)](https://www.natap.org/2023/images/050423/0504231.gif)
Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB) (Global Hepatitis Summit 2023 April 28 Paris)
![Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV) Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV)](https://www.natap.org/2018/images%20/121718/121918-4/1217181.gif)
Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV)
![POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS](https://www.natap.org/2020/images/112020/112020-14/1120203.gif)
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/ PD) MODELS OF JNJ-64794964, A TOLL-LIKE RECEPTOR (TLR)-7 AGONIST, IN HEALTHY ADULT SUBJECTS
![PDF) New instruments in spatial planning: an international perspective on non-financial compensation | Leonie Janssen-Jansen - Academia.edu PDF) New instruments in spatial planning: an international perspective on non-financial compensation | Leonie Janssen-Jansen - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/46822763/mini_magick20220701-24782-14ly09.png?1656687273)
PDF) New instruments in spatial planning: an international perspective on non-financial compensation | Leonie Janssen-Jansen - Academia.edu
![Greenwashing, be gone: Fast 50 companies with sustainability at their heart | Deloitte New Zealand Blog Greenwashing, be gone: Fast 50 companies with sustainability at their heart | Deloitte New Zealand Blog](https://www2.deloitte.com/content/dam/Deloitte/nz/Images/blog/posts/fast%2050%20sustainability%20blog%20inline%20image.jpg)
Greenwashing, be gone: Fast 50 companies with sustainability at their heart | Deloitte New Zealand Blog
![PDF) A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults PDF) A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults](https://i1.rgstatic.net/publication/370886042_A_single_oral_dose_of_the_TLR7_agonist_JNJ-64794964_induces_transcriptomic_and_phenotypic_changes_in_peripheral_immune_cells_in_healthy_adults/links/65698e813fa26f66f4424769/largepreview.png)